Cost of Reaching Defined HbA1c Target Using Canagliflozin Compared to Dapagliflozin as Add-On to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM) in the United Arab Emirates (UAE)
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.2100
https://www.valueinhealthjournal.com/article/S1098-3015(15)04176-5/fulltext
Title :
Cost of Reaching Defined HbA1c Target Using Canagliflozin Compared to Dapagliflozin as Add-On to Metformin in Patients with Type 2 Diabetes Mellitus (T2DM) in the United Arab Emirates (UAE)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)04176-5&doi=10.1016/j.jval.2015.09.2100
First page :
A608
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
1515